Excerpt from:
Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh